HomeCompareELIXF vs PFE

ELIXF vs PFE: Dividend Comparison 2026

ELIXF yields 5970.15% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ELIXF wins by $349757300762301.94M in total portfolio value
10 years
ELIXF
ELIXF
● Live price
5970.15%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$349757300762302.00M
Annual income
$338,600,487,421,434,700,000.00
Full ELIXF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — ELIXF vs PFE

📍 ELIXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodELIXFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ELIXF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ELIXF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ELIXF
Annual income on $10K today (after 15% tax)
$507,462.69/yr
After 10yr DRIP, annual income (after tax)
$287,810,414,308,219,520,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, ELIXF beats the other by $287,810,414,308,219,500,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ELIXF + PFE for your $10,000?

ELIXF: 50%PFE: 50%
100% PFE50/50100% ELIXF
Portfolio after 10yr
$174878650381151.03M
Annual income
$169,300,243,710,717,360,000.00/yr
Blended yield
96.81%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

ELIXF
No analyst data
Altman Z
-68.9
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ELIXF buys
0
PFE buys
0
No recent congressional trades found for ELIXF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricELIXFPFE
Forward yield5970.15%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$349757300762302.00M$49.6K
Annual income after 10y$338,600,487,421,434,700,000.00$26,258.71
Total dividends collected$349006491373237.88M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ELIXF vs PFE ($10,000, DRIP)

YearELIXF PortfolioELIXF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$607,715$597,014.93$9,153$693.39+$598.6KELIXF
2$34,558,188$33,907,932.79$8,593$849.25+$34.55MELIXF
3$1,839,034,548$1,802,057,287.52$8,336$1,066.78+$1839.03MELIXF
4$91,591,647,409$89,623,880,441.98$8,437$1,384.80+$91591.64MELIXF
5$4,269,634,661,039$4,171,631,598,311.20$9,013$1,875.40+$4269634.65MELIXF
6$186,311,225,789,697$181,742,716,702,385.70$10,306$2,680.72+$186311225.78MELIXF
7$7,611,116,385,606,142$7,411,763,374,011,165.00$12,820$4,101.38+$7611116385.59MELIXF
8$291,118,268,537,960,000$282,974,374,005,361,470.00$17,673$6,826.70+$291118268537.94MELIXF
9$10,426,928,355,950,688,000$10,115,431,808,615,070,000.00$27,543$12,591.86+$10426928355950.66MELIXF
10$349,757,300,762,302,000,000$338,600,487,421,434,700,000.00$49,560$26,258.71+$349757300762301.94MELIXF

ELIXF vs PFE: Complete Analysis 2026

ELIXFStock

Elixxer Ltd. operates as a cannabis investment firm in Canada, Australia, Italy, Jamaica, and Switzerland. It invests in cannabis-related businesses, which are fully licensed for cultivation, production, and/or sale of medical and specialty cannabis and cannabis-derived products in the pharmaceutical sector. The company was formerly known as LGC Capital Ltd. and changed its name to Elixxer Ltd. in August 2019. Elixxer Ltd. was incorporated in 2004 and is based in Montreal, Canada.

Full ELIXF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this ELIXF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ELIXF vs SCHDELIXF vs JEPIELIXF vs OELIXF vs KOELIXF vs MAINELIXF vs JNJELIXF vs MRKELIXF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.